← Eurofins Scientific overview

Eurofins Scientific vs Sansure Biotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Eurofins Scientific SE (ERF.PA)

Q3 2026
▲4

Eurofins sharpens focus on life sciences with buybacks and deals

  • Strong first-half results and record cash conversion Eurofins reported 29% earnings-per-share growth, a record 47% cash conversion and EUR 200 million of share buybacks in the first half. Stronger profits and cash give the company more room to invest and return money to shareholders, which supports the shares.

    This is the period's core company result and the main fundamental driver of the stock.

  • Ongoing share buybacks support the stock Eurofins kept buying back its own shares through July and August, repurchasing 85,000 shares one week and 100,000 the next. Buybacks reduce the number of shares in circulation and signal management confidence, which tends to support the share price.

    Buybacks are a repeated but still active capital-return signal that helps explain price support.

  • Portfolio reshaped toward core life sciences testing Eurofins completed the EUR 575 million sale of its MET Labs electrical testing unit and the USD 400 million purchase of Element's North American life sciences business. It is swapping a non-core asset for 27 labs and over USD 150 million of annual revenue in a region where it was underrepresented.

    These two completed deals are the period's biggest strategic moves and directly affect future growth and capital allocation.

  • Growing market for preclinical cell-based testing A new report forecasts the preclinical cell-based assay services market to grow from about USD 4.5 billion in 2025 to USD 12.9 billion by 2035, with Eurofins named among the leading providers. A larger market gives Eurofins more room to win new testing work.

    This is the period's main demand-side signal for Eurofins' core testing business.

August 2026
▲4

Eurofins sharpens focus on life sciences with buybacks and deals

  • Strong first-half results and record cash conversion Eurofins reported 29% earnings-per-share growth, a record 47% cash conversion and EUR 200 million of share buybacks in the first half. Stronger profits and cash give the company more room to invest and return money to shareholders, which supports the shares.

    This is the period's core company result and the main fundamental driver of the stock.

  • Ongoing share buybacks support the stock Eurofins kept buying back its own shares through July and August, repurchasing 85,000 shares one week and 100,000 the next. Buybacks reduce the number of shares in circulation and signal management confidence, which tends to support the share price.

    Buybacks are a repeated but still active capital-return signal that helps explain price support.

  • Portfolio reshaped toward core life sciences testing Eurofins completed the EUR 575 million sale of its MET Labs electrical testing unit and the USD 400 million purchase of Element's North American life sciences business. It is swapping a non-core asset for 27 labs and over USD 150 million of annual revenue in a region where it was underrepresented.

    These two completed deals are the period's biggest strategic moves and directly affect future growth and capital allocation.

  • Growing market for preclinical cell-based testing A new report forecasts the preclinical cell-based assay services market to grow from about USD 4.5 billion in 2025 to USD 12.9 billion by 2035, with Eurofins named among the leading providers. A larger market gives Eurofins more room to win new testing work.

    This is the period's main demand-side signal for Eurofins' core testing business.

Latest
▲4

Eurofins sharpens focus on life sciences with buybacks and deals

  • Strong first-half results and record cash conversion Eurofins reported 29% earnings-per-share growth, a record 47% cash conversion and EUR 200 million of share buybacks in the first half. Stronger profits and cash give the company more room to invest and return money to shareholders, which supports the shares.

    This is the period's core company result and the main fundamental driver of the stock.

  • Ongoing share buybacks support the stock Eurofins kept buying back its own shares through July and August, repurchasing 85,000 shares one week and 100,000 the next. Buybacks reduce the number of shares in circulation and signal management confidence, which tends to support the share price.

    Buybacks are a repeated but still active capital-return signal that helps explain price support.

  • Portfolio reshaped toward core life sciences testing Eurofins completed the EUR 575 million sale of its MET Labs electrical testing unit and the USD 400 million purchase of Element's North American life sciences business. It is swapping a non-core asset for 27 labs and over USD 150 million of annual revenue in a region where it was underrepresented.

    These two completed deals are the period's biggest strategic moves and directly affect future growth and capital allocation.

  • Growing market for preclinical cell-based testing A new report forecasts the preclinical cell-based assay services market to grow from about USD 4.5 billion in 2025 to USD 12.9 billion by 2035, with Eurofins named among the leading providers. A larger market gives Eurofins more room to win new testing work.

    This is the period's main demand-side signal for Eurofins' core testing business.

Sansure Biotech Inc (688289.CG)

Q3 2026
▼2▲1

Sansure's profit slumps on price cuts and tax hike despite new product approvals

  • First-half profit plunges 39.76% on price cuts and tax hike Sansure's first-half net profit fell 39.76% to 98 million yuan as reagent prices dropped from centralized procurement and medical insurance cost controls, and the VAT rate on test reagents jumped from 3% to 13%. This weak profit picture is the main force pushing the stock down.

    This is the biggest new negative force on the stock and explains the core earnings deterioration.

  • Operating cash flow turns negative, adding financial strain The interim report showed operating cash flow was negative 15.66 million yuan, meaning the business burned cash in the first half. Combined with the profit drop, this raises concerns about near-term financial health and pressures the stock.

    Negative cash flow is a new financial red flag that adds to the profit decline.

  • New product approvals expand testing menu and international reach Sansure won approvals for a Group A Streptococcus test, a freeze-dried four-in-one respiratory test, a dengue/chikungunya combo, and EU CE IVDR certification for five products including Class D HIV/HBV/HCV tests. These broaden future revenue sources and support long-term growth.

    These approvals are the main positive pipeline news that could offset weak current earnings over time.

  • Dividend and shareholder enforcement send mixed signals Sansure plans a cash dividend of 2.65 yuan per 10 shares, returning about 151 million yuan to shareholders. But former shareholder Chen Wenyi faces judicial enforcement of 5.71 million shares (0.99% of capital), which could add selling pressure. The dividend supports the stock; the forced share sale weighs on it.

    This captures both the positive capital return and the negative overhang from forced share sales.

August 2026
▼2▲1

Sansure's profit slumps on price cuts and tax hike despite new product approvals

  • First-half profit plunges 39.76% on price cuts and tax hike Sansure's first-half net profit fell 39.76% to 98 million yuan as reagent prices dropped from centralized procurement and medical insurance cost controls, and the VAT rate on test reagents jumped from 3% to 13%. This weak profit picture is the main force pushing the stock down.

    This is the biggest new negative force on the stock and explains the core earnings deterioration.

  • Operating cash flow turns negative, adding financial strain The interim report showed operating cash flow was negative 15.66 million yuan, meaning the business burned cash in the first half. Combined with the profit drop, this raises concerns about near-term financial health and pressures the stock.

    Negative cash flow is a new financial red flag that adds to the profit decline.

  • New product approvals expand testing menu and international reach Sansure won approvals for a Group A Streptococcus test, a freeze-dried four-in-one respiratory test, a dengue/chikungunya combo, and EU CE IVDR certification for five products including Class D HIV/HBV/HCV tests. These broaden future revenue sources and support long-term growth.

    These approvals are the main positive pipeline news that could offset weak current earnings over time.

  • Dividend and shareholder enforcement send mixed signals Sansure plans a cash dividend of 2.65 yuan per 10 shares, returning about 151 million yuan to shareholders. But former shareholder Chen Wenyi faces judicial enforcement of 5.71 million shares (0.99% of capital), which could add selling pressure. The dividend supports the stock; the forced share sale weighs on it.

    This captures both the positive capital return and the negative overhang from forced share sales.

Latest
▼2▲1

Sansure's profit slumps on price cuts and tax hike despite new product approvals

  • First-half profit plunges 39.76% on price cuts and tax hike Sansure's first-half net profit fell 39.76% to 98 million yuan as reagent prices dropped from centralized procurement and medical insurance cost controls, and the VAT rate on test reagents jumped from 3% to 13%. This weak profit picture is the main force pushing the stock down.

    This is the biggest new negative force on the stock and explains the core earnings deterioration.

  • Operating cash flow turns negative, adding financial strain The interim report showed operating cash flow was negative 15.66 million yuan, meaning the business burned cash in the first half. Combined with the profit drop, this raises concerns about near-term financial health and pressures the stock.

    Negative cash flow is a new financial red flag that adds to the profit decline.

  • New product approvals expand testing menu and international reach Sansure won approvals for a Group A Streptococcus test, a freeze-dried four-in-one respiratory test, a dengue/chikungunya combo, and EU CE IVDR certification for five products including Class D HIV/HBV/HCV tests. These broaden future revenue sources and support long-term growth.

    These approvals are the main positive pipeline news that could offset weak current earnings over time.

  • Dividend and shareholder enforcement send mixed signals Sansure plans a cash dividend of 2.65 yuan per 10 shares, returning about 151 million yuan to shareholders. But former shareholder Chen Wenyi faces judicial enforcement of 5.71 million shares (0.99% of capital), which could add selling pressure. The dividend supports the stock; the forced share sale weighs on it.

    This captures both the positive capital return and the negative overhang from forced share sales.